Evidence map›Paper›PMID 36334130›Full record

ArticleSports medicine - open2022

Does Hypoxia and Stress Erythropoiesis Compromise Cardiac Function in Healthy Adults? A Randomized Trial.

Antonio L Arrebola-Moreno, Rafael A Casuso, Jacob Bejder, Thomas Christian Bonne, Andreas Breenfeldt Andersen, Jerónimo Aragón-Vela, Nikolai B Nordsborg, Jesús R Huertas

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Sports medicine - open, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04227665 (Identification of Biological Markers for Hypoxic Exposure and Use of Recombinant Human Erythropoietin), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 73% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04227665 naactive not recruitingnot on this map

Identification of Biological Markers for Hypoxic Exposure and Use of Recombinant Human Erythropoietin

TypeinterventionalSponsorUniversity of CopenhagenRan2018 to 2027Enrolled40ConditionsHealthyArmsSea level, Altitude
3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 3 countries.

Antonio L Arrebola-Moreno *Cardiology Department, HLA Inmaculada Hospital, Granada, Spain.
Rafael A Casuso *Department of Physiology, Institute of Nutrition and Food Technology, University of Granada, Granada, Spain. rcasuso@uloyola.es.
Jacob BejderDepartment of Nutrition, Exercise and Sports (NEXS), University of Copenhagen, Copenhagen, Denmark.
Thomas Christian BonneDepartment of Nutrition, Exercise and Sports (NEXS), University of Copenhagen, Copenhagen, Denmark.
Andreas Breenfeldt AndersenDepartment of Nutrition, Exercise and Sports (NEXS), University of Copenhagen, Copenhagen, Denmark.
Jerónimo Aragón-VelaDepartment of Physiology, Institute of Nutrition and Food Technology, University of Granada, Granada, Spain.
Nikolai B NordsborgDepartment of Nutrition, Exercise and Sports (NEXS), University of Copenhagen, Copenhagen, Denmark.
Jesús R HuertasDepartment of Physiology, Institute of Nutrition and Food Technology, University of Granada, Granada, Spain. jhuertas@ugr.es.ORCID http://orcid.org/0000-0002-7446-0857
University of Copenhagen · DKUniversidad de Granada · ESHospital La Inmaculada · ES

Funding

World Anti-Doping Agency ISF17R02NN
6 · The paper itself

Abstract

objectivesTo investigate whether recombinant human erythropoietin (rHuEPO) injections during an altitude training camp impact heart function.

methodsThirty (12 women) moderately trained subjects stayed at 2320 m altitude for 4 weeks while training. Subjects were randomized to placebo (isotonic saline) or rHuEPO (20 IU/kg body weight) i.v. injections. Transthoracic echocardiography imaging was acquired 3 days after arrival to altitude and prior to the first placebo or rHuEPO injection as well as one day after the last rHuEPO injection three weeks later.

resultsrHuEPO did not alter cardiovascular morphology parameters, systolic or diastolic function. In the placebo group, altitude exposure improved left ventricle (LV) systolic function due to an increased twist angle but rHuEPO had no additional effects. Pulmonary arterial systolic pressure was unaffected in either group. Notably, rHuEPO hampered LV untwist rate without affecting LV early filling.

conclusionrHuEPO provided during mild altitude exposure does not cause any major effects on heart function. The observed alteration in LV untwist induced by rHuEPO is unlikely to have a meaningful clinical effect. Trial Registration Registered on www. CLINICALTRIALS: gov (NCT04227665).

Indexed as

AltitudeDopingHaematologyHeart

Identifiers

PMID36334130
PMCPMC9637068
OpenAlexW4308262343

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.